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Background: The goal of the present study was to explore the effect of medications that are commonly prescribed
for CKD patients on uremic state.
Methods: This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage
kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from
the database were 1) serum C-reactive protein (CRP)> 3 mg/dL, 2) WBC count> 9,000/mm3 or <4,000/mm3, and 3)
patients with cancer, immune complex disease, or vasculitis. A total of 900 patients were entered into the final
database. We explored the association of serum CRP just before the first HD session with clinical characteristics,
laboratory data, and medications for CKD in the predialysis period.
Results: On univariate analysis, age, CTR, eGFR, and WBC were significantly correlated with CRP. Systolic and
diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Use of
erythropoietin-stimulating agents (ESA) using (r =−0.111, p = 0.0015), renin-angiotensin-aldosterone system
inhibitors (r =−0.083, p = 0.0154), and calcium channel blockers (r =−0.1, p = 0.0039) was also negatively correlated
with CRP. However, only use of ESA showed a significant negative correlation with CRP that was independent of
other clinical factors and CKD medications on multiple regression analysis.
Conclusion: ESA may strongly reduce uremic inflammation in addition to improving anemia. To confirm this
potential effect, a large-scale longitudinal study would be required.
Keywords: Inflammation, CRP, Erythropoietin stimulating agent, ACE-I/ARB, Initiation of dialysisBackground
Although the mechanism of cardio-renal syndrome has
been elucidated in considerable detail during the past
decade [1], atherosclerotic cardiovascular disease is still
the leading cause of death in patients with chronic kidney
disease (CKD) [2,3]. Along with the accumulation of
traditional atherogenic risk factors, factors specific to
uremia, such as anemia, dyslipidemia, abnormal calcium
(Ca)/phosphate (P) metabolism, insulin resistance, oxida-
tive stress, malnutrition, and inflammation, play an im-
portant role in such rapid progression of atherosclerosis
[4,5]. In particular, chronic inflammation and oxidative* Correspondence: jokinobuhiko@gmail.com
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reproduction in any medium, provided the orstress are thought to be possible treatment targets in the
clinical setting [6].
According to the international guidelines [2], strict
blood pressure control by using an renin-angiotensin-
aldosterone (RAS) system blocker combined with other
antihypertensive agents, regulation of calcium/phosphate
metabolism with vitamin D or calcium therapy, and
maintaining an optimum hemoglobin concentration with
erythropoietin-stimulating agents (ESAs) and iron are
three main essential treatments for renoprotection and a
better prognosis in CKD patients. Recently, it has been
suggested that medications for CKD could have possible
pleiotropic effects, especially an anti-inflammatory effect.
For instance, RAS blockers [7], vitamin D [8], and ESA
[9] have already been shown to have anti-inflammatory
activity in clinical and basic studies. However, there isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ments for CKD on inflammation in the clinical setting.
The goal of the present study was to explore the effect
of medications that are commonly used by CKD patients
on the serum level of C-reactive protein (CRP) at the
initiation of renal replacement therapy (RRT).
Patients and methods
Study design & patients
We conducted a cross-sectional study using the database
of the “Study Group for Assessing Initiation of Renal Re-
placement Therapy” (START), which includes the neph-
rology unit of nine institutions in Japan. The objective of
START is to create a shared database on end-stage kid-
ney disease (ESKD) patients at the time of starting RRT
for the conduct of clinical research. From January 2006
to October 2009, 1,623 ESKD patients commenced
chronic hemodialysis (HD) at the 9 hospitals and clinical
information on those patients was added to the START
database. In order to explore the anti-inflammatory ef-
fect of CKD medications, the following exclusion criteria
were employed: 1) patients with an abnormal white
blood cells count> 9,000/mm3 or <4,000/mm3, 2)





















Figure 1 Disposition of the subjects.such as those with cancer, immune complex disease, or
vasculitis, and 3) in order to minimize the contamin-
ation of high CRP caused by infectious disease, the
patients with a serum CRP level >3 mg/dL were also
eliminated from final database according to the results
of DOPPS data [10] which shows that CRP level was less
than 2.5 mg/dL in 95% of Japanese stable dialysis
patients. As a result, 900 ESKD patients were available
for the final database of this study (Figure 1). In order to
examine the factors associated with inflammation during
the predialysis phase of CKD, we compared the serum
CRP concentration just before the first HD session with
clinical characteristics, laboratory data, and medications
for CKD in the predialysis period. CKD treatments were
classified as ESA, angiotensin-converting enzyme inhibi-
tors (ACE-I), angiotensin-II receptor blockers (ARB),
calcium channel blockers (CCB), other anti hypertensive
agents (anti-HT), vitamin D, calcium supplements, iron
supplements, and AST-120. As ESA therapy, epoetin-alfa
& beta were used for renal anemia during the study
period of 2006 to 2009. The last medication (AST-120)
is a carbonaceous adsorbent that is used to treat CKD
patients in Japan. It has been reported that AST-120
removes uremic toxins and reduces oxidative stressiteria
BC; 4000-9000/cmm
iteria
ncer, immune complex disease
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Toho University Ohashi Medical Center approved the
study protocol (permission no. 13-22).
Data collection
Clinical information was recorded on all patients at each
nephrology unit immediately prior to first HD session
using the same protocol. First, each patient was inter-
viewed to obtain data on the age, gender, smoking
habits, primary renal disease, previous hospitalizations,
and history of hypertension, cardiac disease, cerebrovas-
cular disease, and peripheral artery disease. We also col-
lected information about the use of oral medications and
erythropoietin during the predialysis period. Blood pres-
sure was recorded in the supine position and a blood
sample was collected just before the first HD session.
The estimated glomerular filtration rate was calculated
by using the new Japanese equation [13]:
eGFR mL=min=1:73 m2
  ¼ 194 Cr1:094
 age0:287
 0:739 for womenð Þ:
The body mass index (BMI) at optimal weight was cal-
culated as the weight in kilograms divided by the square
of the height in meters. The cardiothoracic ratio (CTR)
was determined at the optimal body weight after HD.
Statistical analysis
Data are expressed as the mean± SD. To assess the asso-
ciation of various factors with inflammation, Pearson’s
univariate regression analysis was employed to compare
clinical factors with CRP. Dummy variables were used
for gender (0 for female, 1 for male), primary renal dis-
ease (0 for non-diabetic nephropathy, 1 for diabetic
nephropathy), smoking history (0 for negative, 1 for
positive), and each CKD treatment (0 for not used, 1 for
used). The monthly ESA dose was evaluated as a numer-
ical factor. Multivariate regression analysis was also per-
formed to identify independent determinants of the
serum CRP concentration. In all analyses, a probability
(P) value< 0.05 was considered statistically significant.
All statistical analyses were performed using StatView
for Windows version 5.0 (SAS Institute, Cary, NC).
Results
Demographic characteristics of 900 new dialysis patient
who enrolled into the study
The mean age was 65.5±13.7 years (range: 14 to 93 years).
The percentage of men (68%) and the percentage of
patients with diabetic nephropathy (48%) were similar to
those previously reported at the initiation of dialysis for the
entire Japanese dialysis population [14]. The mean Cr and
eGFR at the initiation of RRT were 9.5±3.5 mg/dL and5.4±2.9 mL/min/1.73 m2, respectively, which were similar
to the levels for the Japanese dialysis population [14].
Therefore, our database seemed to be a suitable sample of
Japanese dialysis patients. The mean duration of care by a
nephrologist in the predialysis phase of CKD was
33±43 months. Other clinical characteristics are shown in
Table 1. The mean CRP level at the initiation of RRT was
used as a marker of chronic inflammation during the pre-
dialysis phase of CKD; it was 0.48±0.68 mg/dL. In 133
(14.8%) of the 900 patients, the serum CRP concentration
was 0.0 mg/dL, while 585 patients (65%) had a CRP in the
normal range of ≤0.3 mg/dL.
During the predialysis phase of CKD, about 70% of
our subjects used ESA and the mean monthly dose was
17813 ± 6580 units. About 60% and 20% were using RAS
inhibitor and vitamin D, respectively. Other medications
are shown in Table 1.
Univariate analysis of factors associated with CRP
Among clinical characteristics, the age (r = 0.136, p
< 0.0001), CTR (r = 0.134, p = 0.0003), eGFR (r = 0.122,
p = 0.0002), and WBC (r = 0.14, p = 0.0005) were signifi-
cantly correlated with the serum CRP level, as shown in
Table 2. Systolic blood pressure (r =−0.087, p = 0.0113),
diastolic blood pressure (r =−0.068, p = 0.0484), serum
albumin (r =−0.246, p< 0.0001), LDL-C (r =−0.084,
p = 0.0341), HDL-C (r =−0.153, p< 0.0001), Hb
(r =−0.11, p = 0.001), Cr (r =−0.102, p = 0.0023), and Ca
(r =−0.118, p = 0.0004) were inversely correlated with
the CRP concentration.
Univariate analysis of CKD treatments associated with
CRP
Because the duration of care by a nephrologist before
starting RRT was thought to influence the association of
CKD treatments with CRP, all treatments were adjusted
by the “duration of nephrologist care,” which did not
show a significant correlation with CRP (r =−0.06,
p = 0.0775). As shown in Table 3, use of ESA (r =−0.111,
p = 0.0015) and the dose of ESA (r =−0.117, p = 0.0017),
use of ARB (r =−0.076, p = 0.0275), use of ARB or ACE-I
(r =−0.083, p = 0.0154) (corresponding to use of RAS-I),
and use of CCB (r =−0.1, p = 0.0039) were negatively
correlated with the CRP level. Strongest inverse associ-
ation was observed between CRP and ESA using, as
shown in Figure 2.
Multivariate analysis of CKD treatments associated with
CRP
In order to examine whether any CKD treatments were
independent determinants of CRP, we performed further
analyses using multivariate linear regression models
(Table 4). In the first model, ESA and CCB showed an
independent inverse correlation with CRP among CKD
Table 1 Clinical characteristics of the study population
Age, years 65.5 ± 13.7
Male sex (%) 611 (67.9)
BMI, kg/m2 23.0 ± 4.0
SBP, mmHg 153± 26
DBP, mmHg 78 ± 15
CTR, % 54± 7
Primary disease
Chronic glomeruronephritis 226 (25.1)
Diabetic nephropathy 432 (48.0)
Glomerulosclerosis 104 (11.6)
Polycystic kidney disease 28 (3.1)
Post-renal disease 5 (0.6)
Others 105 (11.6)
Duration of nephrologist care, months 33 ± 43
WBC, /mm3 6160± 1270
Hemoglobin, g/dL 8.5 ± 1.5
Plt x 104, mm3 19.4 ± 7.1
Albumin, g/dL 3.3 ± 0.6
LDL-C, mg/dL 98 ± 41
HDL-C, mg/dL 47 ± 17
Creatinin, mg/dL 9.5 ± 3.5
BUN, mg/dL 89 ± 27
Uric acid, mg/dL 8.6 ± 2.2
eGFR, mL/min/1.73 m2 5.4 ± 2.9
Calcium, mg/dL 7.8 ± 1.0
Phosphate, mg/dL 6.0 ± 1.6
Intact-PTH, pg/mL 304 ± 214
CRP, mg/dL 0.48 ± 0.68
HCO3-, mmol/L 18.9 ± 5.0
ESA (%) 614 (68.2)
ESA dose, u/month 17813± 6580
ARB (%) 489 (54.3)
ACE-I (%) 165 (16.3)
ARB or ACE-I (%) 541 (60.1)
ARB and ACE-I (%) 113 (12.6)
CCB (%) 565 (62.8)
other anti-HT drugs (%) 315 (35.0)
Vitamin D (%) 174 (19.3)
Calcium agents (%) 271 (30.1)
Iron agents (%) 85 (9.4)
AST-120 (%) 160 (17.8)
BMI; body mass index, SBP; systolic blood pressure, DBP; diastolic blood
pressure, CTR; Cardiothoracic ratio, WBC; white blood cell, Plt; platelets, LDL-C;
low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholesterol,
BUN; blood urea nitrogen, eGFR; estimated glomerular filtration rate, PTH;
parathyroid hormone, CRP; C-reactive protein, ESA; erythropoietin-stimulating
agents, ARB; angiotensin-II receptor blockers, ACE-I; angiotensin-converting
enzyme inhibitors, CCB; calcium channel blockers, anti-HT; antihypertensive.
Table 2 Univariate linear regression analysis of factors
correlated with the serum CRP concentration
Variable Regression coefficient p value
Age 0.136 <0.0001
Sex (F: 1, M: 2) 0.004 0.897




















ESA dose −0.124 0.0007
ARB −0.071 0.0361
ACE-I −0.052 0.1282
ARB or ACE-I −0.075 0.0261
ARB and ACE-I −0.059 0.0841
CCB −0.1 0.0032
other anti-HT −0.065 0.0562
AST-120 −0.036 0.2943
Vitamin D −0.058 0.0863
Iron agents −0.072 0.1059
BMI; body mass index, SBP; systolic blood pressure, DBP; diastolic blood
pressure, CTR; Cardiothoracic ratio, WBC; white blood cell, Plt; platelets, LDL-C;
low density lipoprotein cholesterol, HDL-C; high density lipoprotein
cholesterol, BUN; blood urea nitrogen, eGFR; estimated glomerular filtration
rate, PTH; parathyroid hormone, CRP; C-reactive protein, ESA; erythropoietin-
stimulating agents, ARB; angiotensin-II receptor blockers, ACE-I; angiotensin-
converting enzyme inhibitors, CCB; calcium channel blockers, anti-HT;
antihypertensive.
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second model, age and eGFR were added to the first
model, after which use of ESA and CCB still showed a
significant association with CRP. For the third model,
the additional covariates of albumin, LDL-C, HDL-C,
and Hb were added to the first model. Use of RAS-I
showed an independent association with CRP instead of
Table 3 Linear regression analysis of the association
between CKD treatments and the serum CRP
concentration#
Factor Regression coefficient 95%CI p value
ESA −0.111 −0.274 - -0.065 0.0015
ESA dose −0.117 −0.014 - -0.003 0.0017
ARB −0.076 −0.196 - -0.012 0.0275
ACE-I −0.061 −0.221 - 0.012 0.0785
ARB or ACE-I −0.083 −0.212 - -0.022 0.0154
ARB and ACE-I −0.065 −0.267 - 0.005 0.0589
CCB −0.1 −0.241 - -0.046 0.0039
other anti-HT −0.068 −0.188 - 0.001 0.0515
AT-120 −0.041 −0.190 - 0.046 0.2306
Vitamin D −0.064 −0.220 - 0.007 0.0664
Fe −0.086 −0.334 - 0.003 0.054
# All factors are adjusted by the "duration of nephrologist care"
ESA; erythropoietin-stimulating agents, ARB; angiotensin-II receptor blockers,
ACE-I; angiotensin-converting enzyme inhibitors, CCB; calcium channel
blockers, anti-HT; antihypertensive.
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with CRP. For the fourth model, sBP and CTR were
added to the first model, and ESA and CCB were
selected again. Finally, all of the factors were included in
the fifth model and significant correlations of ESA and
RAS-I with CRP were observed. These findings sug-
gested that only use of ESA had a significant inverse cor-
relation with the serum CRP concentration.
Discussion
It is well established that chronic inflammation plays a












Figure 2 The CRP levels of ESKD patients with and without ESA
using at the initiation of renal replacement therapy. Significantly
less CRP concentration was found in ESA user compared with non-
user by using student’s t-test (0.42 ± 0.65 mg/dL vs. 0.61 ± 0.76 mg/
dL). Solid line depicts the correlation coefficient by means of
Pearson’s univariate regression analysis (r =−0.119, p = 0.0005).cardiovascular disease in CKD patients [15-17]. There is
increasing evidence of a relationship between the serum
level of CRP, a marker of chronic inflammation, and
cardiovascular disease in these patients [15,18]. The
present study demonstrated that at the initiation of
RRT 1) 35% of ESKD patients had abnormally high
CRP levels; 2) CRP was positively correlated with age,
CTR, and eGFR, and negatively correlated with blood
pressure, albumin, HDL-C, HDL-C, and Hb; 3) use of
ESA showed an independent inverse correlation with
CRP. These findings imply that use of ESA in the pre-
dialysis phase of CKD has an anti-inflammatory effect
and would be beneficial for prevention of progression
of atheroscletic complications.
Chronic inflammation is thought to be one of the cen-
tral reasons for the high incidence and prevalence of
atherosclerotic cardiovascular disease in CKD patients
[16]. CRP is a well known marker of inflammation in the
general population [19]. In CKD patients, it has been
reported that CRP is closely associated with the severity
of atherosclerosis and cardiovascular events [17,18]. In-
deed, several reports have suggested that CRP could be
associated with atherosclerosis through various mechan-
ism such as 1) release of reactive oxygen species, 2)
increased expression of adhesion molecules, 3) induction
of foam cell formation, and 4) destabilization of plaque
[6]. If CRP is involved in the pathophysiology of cardio-
vascular disease, it could be expected that reducing the
CRP level would prevent the development of cardiovas-
cular complications. In the present study, use of ESA,
RAS-I, and CCB during the predialysis period showed a
significant inverse correlation with serum CRP. Al-
though we do not have any information about the dur-
ation of such treatments in the predialysis phase of
CKD, the effect of each medication on CRP remained
significant after adjustment for the duration of care by a
nephrologist. This may imply that ESA, RAS-I, and CCB
have an anti-inflammatory effect in the predialysis phase
of CKD which is independent of the duration of
treatment.
Treatment with RAS-I is well known to reduce
chronic inflammation in CKD patients. In the current
study, 60% of the subjects were on treatment with RAS-
I in the predialysis period and most of them received
ARB. At least 6 ARB are recognized to have an anti-in-
flammatory effect and have been shown to reduce CRP
in clinical studies. Dohi et al [20]. reported that cande-
sartan treatment for 12 weeks decreased the serum level
of CRP by 14% in patients with essential hypertension.
In addition, valsartan therapy for 8 months reduced CRP
by 39% in hypertensive patients with left ventricular
hypertrophy [21] or with other cardiovascular risk fac-
tors [22], while 3 months of irbesartan therapy for
patients with coronary artery disease significantly
Table 4 Multiple linear regression analysis of factors associated with the serum CRP concentration
Model 1 Model 2 Model 3 Model 4 Model 5






Regression coefficient p value Regression coefficient p value Regression coefficient p value
Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper
Age 0.124 0.0003 0.112 0.0115
0.003 0.01 0.001 0.01
SBP -0.087 0.0228 -0.099 0.0249
-0.004 -0.0003
CTR 0.134 0.0005 0.011 0.8073
0.006 0.021 -0.008 0.01
Albumin −0.262 <0.0001 -0.27 <0.0001
−0.423 −0.224 -0.43 -0.219
LDL-C −0.122 0.0027 -0.107 0.013
−0.003 −0.001 -0.003 0.0004
HDL-C −0.148 0.0003 -0.141 0.0009
−0.009 −0.003 -0.009 -0.002
Hemoglobin −0.043 0.2889 -0.079 0.0761
−0.059 0.018 -0.078 0.004
eGFR 0.09 0.0108 0.077
0.005 0.036 -0.002 0.038 0.084
ESA −0.094 0.0086 −0.075 0.0348 −0.131 0.0014 -0.078 0.0447 -0.116 0.0072
−0.253 −0.037 −0.225 −0.008 −0.354 −0.085 -0.244 -0.003 -0.335 -0.053
ARB or ACE-I −0.054 0.1229 −0.055 0.1159 −0.098 0.0157 -0.054 0.1589 -0.095 0.0258
−0.175 0.021 −0.175 0.019 −0.266 −0.028 -0.184 0.03
CCB −0.088 0.0129 −0.09 0.0097 −0.08 0.052 -0.097 0.0133 -0.077 0.0732
−0.228 −0.027 −0.23 −0.032 −0.247 0.001 -0.249 -0.029 -0.246 0.011
SBP; systolic blood pressure, CTR; Cardiothoracic ratio, LDL-C; low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholesterol, eGFR; estimated glomerular filtration rate, ESA; erythropoietin-stimulating



















Tanaka et al. Journal of Inflammation 2012, 9:17 Page 7 of 9
http://www.journal-inflammation.com/content/9/1/17reduced the plasma CRP level [23]. A large-scale pro-
spective, double-blind, placebo-controlled, multicenter
study performed in patients with essential hypertension
and microinflammation also showed that olmesartan
therapy significantly reduced the serum level of CRP
[24]. Moreover, reduction of serum CRP was observed
after losartan was administered for 28 days to patients
who had interstitial inflammation and fibrosis associated
with chronic cyclosporine-induced nephropathy [25]. Fi-
nally, treatment with telmisartan for 3 months reduced
the serum level of CRP by 38% in diabetic patients [26].
It is interesting that irrespective of the underlying dis-
ease and the duration of treatment, an anti-inflammatory
effect of ARB therapy was confirmed. These reports sup-
port our finding that the beneficial anti-inflammatory ef-
fect of ARB was still detectable after adjusting for the
duration of care by a nephrologist. There have also been
several studies into the effects of ACE-I on CRP in vari-
ous diseases [26-28].
Compared with ARB, less is known about the clinical
effect of CCB on CRP, but a few studies have clearly
shown a suppressive effect of CCB on inflammation.
After 3 months of CCB treatment, reduction of the
serum CRP level was observed in patients with vasospas-
tic angina [29]. Also, the combination of a RAS-I with
the CCB azelnidipine decreased serum CRP more than
combined therapy with other CCB [30]. This implies
that the effect on CRP may depend on the type of CCB.
Unfortunately, no information concerning the type of
CCB was included in our database, so we could not in-
vestigate this issue.
Intriguingly, use of ESA was strongly associated with a
lower CRP level in the current study. This association
remained even after adjusting for RAS-I and CCB, as
well as other variables. Several other reports support our
finding of an inverse association between use of ESA and
the serum level of CRP. To our knowledge, Agnello et al.
first identified a possible anti-inflammatory effect of ESA
in an experimental rat model of autoimmune encephalo-
myelitis [9]. They showed that ESA decreased the peak
clinical severity of experimental autoimmune encephalo-
myelitis in a dose-dependent manner, with a simultan-
eous marked decrease of TNF and the pro-inflammatory
cytokine IL-6 in the spinal cord. In the clinical field,
Kourea et al [31]. demonstrated in their single-blind, pla-
cebo-controlled trial that patients with anemic congestive
heart failure who received combined treatment using the
erythropoietin analogue darbepoietin-α and oral iron had
a greater increase of Hb than those treated with placebo
plus oral iron, and also showed concomitant improve-
ment of cardiac contractility. As a possible mechanism of
this cardioprotective effect, they confirmed an approxi-
mately 40% decrease of IL-6 (a pro-inflammatory cyto-
kine) by treatment with darbepoietin-α, compared withan increase of about 20% after placebo treatment. This
finding suggests that ESA has an anti-inflammatory effect
in patients with sustained inflammation such as those
with heart failure. Since it is well known that IL-6 regu-
lates the hepatic synthesis of CRP, our main finding that
CRP was lower in patients using ESA compared to those
without ESA agrees with the above evidence.
The most popular class of medication with anti-
inflammatory and pleiotropic effects is the statins. Even
in patients with end-stage kidney disease, CRP is
decreased by 11.5% as a result of statin therapy [32].
However no clinical advantage of statin treatment has
been identified in ESKD patients [32,33]. Because there
is little evidence of a beneficial effect of statin therapy
for advanced CKD, statins are still not standard treat-
ment for CKD patients, especially those in stages 4 and
5. Therefore, we did not include information on the use
of statins in our database.
Because the current study had a cross-sectional design,
this is a limitation, since we did not have any informa-
tion about the duration of each treatment in the predia-
lysis phase, apart from the duration of care by a
nephrologist. Based on the hypothesis that there would
be a close association between nephrologist care and
treatment for the predialysis phase of CKD, all treat-
ments were first adjusted by the duration of care. We
consider that this minimized the potential bias. The sec-
ond limitation of our study is that the marker of chronic
inflammation in the predialysis phase of CKD was the
serum CRP level measured just before the first dialysis
session. We could not completely exclude the possibility
that this CRP level did not reflect chronic inflammation
in our uremic patients, although we excluded patients
with suspected infection (defined as those with an ab-
normal WBC count). We also excluded patients who are
susceptible to latent chronic inflammation, including
those with cancer, immune complex disease, or vascu-
litis, from our final database. However, such exclusions
could have narrowed the focus of our investigation.
In conclusion, the present cross-sectional study
explored the potential anti-inflammatory effect of com-
mon CKD medications in the real world clinical setting.
We found that use of ESA had the strongest connection
with lower CRP levels. Accordingly, ESA may reduce
uremic-specific inflammation in addition to the main ef-
fect of these agents on anemia. To confirm these find-
ings, a large-scale longitudinal study will be required.
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